Skip to main content
Premium Trial:

Request an Annual Quote

MDRNA Repays $5.5M Loan to GE Capital


MDRNA this week announced that it has repaid all remaining debt on a $5.5 million loan from General Electric Capital, marking the RNAi drug shop's latest step toward overcoming its financial woes.

"The repayment of this loan removes all liens on our intellectual property, equipment, and other assets, thus providing us maximum flexibility in establishing broad target and therapeutic-based pharma collaborations," MDRNA President and CEO Michael French said in a statement.

MDRNA has struggled under a cash crunch since it was created last summer out of now-defunct nasal drug-delivery firm Nastech Pharmaceutical (see RNAi News, 6/12/2008).

Since that time, the company has worked to realize value from its non-RNAi assets (see RNAi News, 2/5/2009 & 4/2/2009), while out-licensing portions of its technology platform to big pharma (see RNAi News, 2/19/2009 & 3/26/2009).

These and other efforts have helped bolster MDRNA's stock, which closed at $1.63 on Monday, up significantly from a 52-week low of $0.14 a share but still off a 52-week high of $3.55.

The Scan

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Gene Linked to Alkaline Sensitivity in Plants Identified

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.